Protocol of the DiaDec-study: Quality of life, health care utilisation and costs in patients with diabetes: The role of depression
Journal Title: Journal of Diabetology and Endocrinology - Year 2016, Vol 1, Issue 2
Abstract
Diabetes is a highly prevalent chronic disease with a substantial impact on quality of life and societal cost. Depressive disorders have been found to be more prevalent among individuals with diabetes than those without diabetes. Studies reported 4.5-times higher total annual healthcare costs for Medicare patients with comorbid diabetes and depression than for patients with diabetes but no comorbid depression. Data regarding the appropriateness of treatment and treatment outcomes in the real world setting for patients with diabetes and a depressive disorder is lacking. Our aim is to investigate the prevalence of undiagnosed and diagnosed depression and to describe health-related quality of life and health care utilisation and costs in a German sample of individuals with diabetes and comorbid depression. The DiaDec study is based on a random sample of a statutory health insurance (SHI) population with diabetes. In a baseline survey, participants were assessed with respect to subthreshold and major depression and health-related quality of life. Data on diagnosed depression, amount and cost of prescribed medications, and outpatient and inpatient care was extracted from health insurance records for each study participant. By linking the survey data with longitudinal health insurance data the association between depression status, quality of life and health care utilisation/costs in the year before and after the survey will be investigated. We expect that our results will foster discussion on the quality and cost-effectiveness of health care for patients with diabetes and a comorbid depression.
Authors and Affiliations
Kvitkina T, Brune M, Chernyak N, Begun A, Andrich S, Linnenkamp U, Fiege A, Claessen H, Emmel C, Jaffan-Kolb L, Arend W, Schmitz-Losem I, Fabricius V, Kruse J, Icks A
Keywords
Related Articles
- EP ID EP556699
- DOI 10.14312/2398-0281.2016-3
- Views 50
- Downloads 0
Metformin in type 2 diabetes: where is the evidence?
Taking into consideration the main evidence available in 2015, Boussageon contest the status of metformin as the first -line treatment for DT2 patients. He contends that as regards macrovascular and microvascular complic...
Disuse osteoporosis: A better understanding of pathophysiology may lead to potential therapies
Amputation results in mechanical unloading of a previously weight bearing limb with subsequent focal decrease in bone mineral density (BMD), and the development of disuse osteoporosis. We report the case of a 44-year-old...
Long-term correction of diabetic hyperglycemia through glucose-responsive hepatic insulin production using lentivirus
Type 1 diabetes mellitus (T1DM) is caused by the autoimmune destruction of the insulin-producing β cells of the pancreas. Insulin gene therapy is a promising strategy capable of overcoming the limitations of current trea...
A comparative analysis of pharmacists' self-confidence beliefs for regular U-500 (concentrated) insulin and U-100 insulin
The purpose of this research was to assess pharmacist confidence levels in the accurate and safe counseling on Humulin R regular U-500 (concentrated) insulin compared to U-100 insulin. The investigators developed a 34-it...
Protocol of the DiaDec-study: Quality of life, health care utilisation and costs in patients with diabetes: The role of depression
Diabetes is a highly prevalent chronic disease with a substantial impact on quality of life and societal cost. Depressive disorders have been found to be more prevalent among individuals with diabetes than those without...